https://www.renaissancecapital.com/IPO-Center/News/87298/Inflammatory-disease-biotech-Ventyx-Biosciences-sets-terms-for-$125-million
VTYX IPO News - Inflammatory disease biotech Ventyx Biosciences sets terms for $125 million IPO
Ventyx Biosciences, a Phase 1 biotech developing selective therapies for inflammatory and autoimmune diseases, announced terms for its IPO on Friday.The...
https://theorg.com/org/ventyx-biosciences?person=preeti-baweja
Ventyx Biosciences | The Org
Ventyx Biosciences is a biotechnology company with a diverse portfolio of best-in-class highly differentiated clinical and pre-clinical stage programs focused...
biosciences